復星醫藥(600196.SH):就與Lilly簽署許可協議 現對主要付款安排作補充
格隆匯 11 月 1日丨復星醫藥(600196.SH)公佈,公司於2020年10月30日披露《關於控股子公司簽署許可協議的公告》,內容有關公司控股子公司重慶復創醫藥研究有限公司(“復創醫藥”)授予Eli Lilly and Company(“Lilly”)在區域內(除中國大陸、香港及澳門特別行政區外所有國家及地區)及領域內(包括診斷、預防、改善及治療人類或動物的任何疾病或症狀在內的所有用途,下同)BCL-2選擇性小分子抑制劑FCN-338獨家研發、生產及商業化的權利。現就此次合作主要付款安排作如下補充:
Lilly應根據約定向復創醫藥支付至多4.4億美元(包括首付款、臨牀開發注冊及銷售里程碑付款),具體安排如下:
1、首付款4000萬美元,於《許可協議》生效之日起30日內支付。
2、臨牀開發註冊里程碑付款合計不超過3.4億美元,根據如下安排支付:
(1)根據該產品針對約定適應症的臨牀試驗階段,累計支付不超過1.3億美元;
(2)根據該產品於約定地區/國家一獲批上市進展,累計支付不超過1.3億美元;
(3)根據該產品於約定的其他地區/國家獲批上市進展,累計支付不超過8000萬美元。
3、銷售里程碑付款合計不超過6000萬美元,根據該產品在區域內年度淨銷售額的達成情況向復創醫藥分別支付1000萬美元、2000萬美元、3000萬美元的里程碑付款。
4、銷售提成Lilly應於《許可協議》約定的銷售提成期間內,根據該產品於區域內年度淨銷售額的達成情況,按約定的比例區間(4%-8%)支付銷售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.